MedTrace Logo

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16

NCT06410131 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-07-01

No results posted yet for this study

Summary

This is an open, multi-center, multi-cohort phase I clinical study designed to evaluate safety, tolerability, pharmacokinetics and initial efficacy of FTL008.16 in patients with advanced and metastatic solid tumors.

Conditions

Interventions

DRUG

FTL008.16

IV infusion every 2 weeks

Sponsors & Collaborators

  • Sound Biopharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Ning Li, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Shoubin Wen, MD · Sound Biopharmaceuticals Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2026-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06410131 on ClinicalTrials.gov